Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Iolyx Australia
Melbourne, Victoria, Australiaiolyx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Iolyx is an Australian biotechnology company focused on the development of novel small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary research focus is on the inhibition of Interleukin-1 receptor-associated kinase 4 (IRAK4), a critical signaling node in the innate immune response. By targeting this pathway, Iolyx aims to address unmet medical needs in chronic inflammatory conditions such as rheumatoid arthritis and various dermatological diseases. The company operates within the Australian life sciences ecosystem, leveraging local R&D incentives to advance its early-stage pipeline toward clinical validation.
- Therapeutic areas
- RheumatologyDermatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Iolyx Australia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iolyx Australia.